Glycosyltransferases that act on polyprenol pyrophosphate substrates are challenging to study because their lipid-linked substrates are difficult to isolate from natural sources and arduous to synthesize. To facilitate access to glycosyl acceptors, we assembled phosphonophosphate analogues and showed these are effective substrate surrogates for GlfT1, the essential product of mycobacterial gene Rv3782. Under chemically defined conditions, the galactofuranosyltransferase GlfT1 catalyzes the formation of a tetrasaccharide sequence en route to assembly of the mycobacterial galactan.
Glycosyltransferases that act on polyprenol pyrophosphate substrates are challenging to study because their lipid-linked substrates are difficult to isolate from natural sources and arduous to synthesize. To facilitate access to glycosyl acceptors, we assembled phosphonophosphate analogues and showed these are effective substrate surrogates for GlfT1, the essential product of mycobacterial gene Rv3782. Under chemically defined conditions, the galactofuranosyltransferase GlfT1 catalyzes the formation of a tetrasaccharide sequence en route to assembly of the mycobacterial galactan.
Lipid-linked oligosaccharide
pyrophosphates serve as acceptors for a large class of glycosyltransferases.[1] Progress in understanding these enzymes is hindered
by the difficulty of isolating these biosynthetic acceptors from natural
sources and the challenge of their chemical synthesis.[2,3] Although some acceptors have been generated through astutely orchestrated
syntheses,[4−8] the lability of the allylic pyrophosphoryl group narrows the range
of transformations that can be applied to their synthesis. We envisioned
addressing these barriers by synthesizing a glycosyltransferase acceptor
in which the pyrophosphoryl group was replaced with a phosphonophosphate
group (Figure 1, top). This modification should
mimic key features of the acceptor, while augmenting its hydrolytic
stability and synthetic accessibility.[9] The impetus for testing these surrogates arose from our investigation
of galactan biosynthesis.
Figure 1
Top: Replacement of the allylic phosphate
in 1 (blue)
with a phosphonate (blue) and (2Z,6Z)-farnesyl lipid affords surrogate 2. Bottom: The product
of GlfT1 (denoted with the question mark) is elongated by GlfT2 to
afford the mycobacterial galactan (n = 10–20).
The galactan, a critical component
of the mycobacterial cell wall,
is composed of galactofuranose (Galf), the energetically
disfavored 5-membered ring isomer of galactose.[10,11] Galf has not been identified in any mammalianglycans,
rendering the enzymes that mediate Galf incorporation
potential antimycobacterial targets.[12,13] The essential[14]Mycobacterium tuberculosis gene Rv3782 encodes a protein termed GlfT1. GlfT1 appears to
be a galactofuranosyltransferase that primes galactan assembly. Its
assigned role is to promote the elongation of decaprenyl-linked l-Rha-α-(1,3)-d-GlcNAc pyrophosphate 1 by one to three Galf residues (Figure 1, bottom).[15] The resulting
lipid-linked oligosaccharide is a substrate for the related galactofuranosyltransferase
GlfT2.[13] GlfT2 can process synthetic substrates
bearing even a single galactofuranose residue.[16] In principle, therefore, GlfT1 needs only to catalyze the
addition of one Galf residue to its substrate (Figure 1). Still, experiments with membrane extracts or
cell lysates suggested that GlfT1 could catalyze the addition of multiple
Galf residues.[15,17,18] We sought to assess the enzyme products under chemically defined
conditions, which required obtaining active GlfT1 and a suitable acceptor.The predicted GlfT1 acceptor 1 is a demanding synthetic
target; therefore, we considered which of its features would be required
for function. An analysis of literature suggested that the pyrophosphate
group would be important.[19−21] Consistent with this analysis,
we found that O-alkyl disaccharides lacking a pyrophosphate
linkage, such as 12-phenoxydodec-2-enyl Rha-α-(1,3)-GlcNAc S6, were not elongated by purified, recombinant GlfT1.[22] Attempts to synthesize substrates analogous
to 1 were complicated by the lability of the allylic
pyrophosphate. We therefore considered a modification that would increase
the stability of intermediates en route to the target glycosyl acceptors.
Phosphonophosphates can serve as pyrophosphate analogues, and their
increased stability suggested that they could be more readily synthesized.
We therefore targeted surrogate 2 (Figure 1, top) with the goal of ascertaining whether this compound
could function as a GlfT1 acceptor.Top: Replacement of the allylic phosphate
in 1 (blue)
with a phosphonate (blue) and (2Z,6Z)-farnesyl lipid affords surrogate 2. Bottom: The product
of GlfT1 (denoted with the question mark) is elongated by GlfT2 to
afford the mycobacterial galactan (n = 10–20).In selecting compound 2, we recognized the potential
risk of generating a phosphonophosphate that is not isosteric with
the pyrophosphate. Nevertheless, this risk by the increased synthetic
accessibility of compound 2 and because enzymes, such
as farnesyltransferases, bind lipid-substituted pyrophosphate and
truncated phosphonophosphate derivatives similarly.[23] Because the related glycosyltransferase GlfT2 is influenced
by the acceptor lipid substituent,[13] our
synthetic route was designed to access acceptors with diverse lipid
groups (Scheme 1). The decaprenol substituent
was replaced with a (2Z,6Z)-farnesyl
group, as this shorter lipid substituent can simplify substrate handling.[24] Glycosyltransferases can be sensitive to the
polyprenol lipidalkene and its geometry,[4,7,25] so we preserved the isoprenyl alkene geometry
closest to the oligosaccharide. We reasoned that if compound 2 was inactive, we could modify our route to identify a suitable
substrate.
Scheme 1
Synthesis of GlfT1 Acceptor Surrogate 2
The convergent route shown
was also used to prepare 8 and 9.
Synthesis of GlfT1 Acceptor Surrogate 2
The convergent route shown
was also used to prepare 8 and 9.The route to acceptor surrogate 2 began
with the glycosylation
of compounds 3 and 4. The stereochemical
outcome of the glycosylation was controlled by using the α-selective
silylated l-rhamnosyldonor 3.[26] Activation of this “super armed” donor[27] with N-iodosuccinimide and
silver trifluoromethanesulfonate provided the desired α-glycoside.
The silyl protecting groups were exchanged for acetate groups, as
unmasking the former late in the synthetic route was problematic.
This protecting group change facilitated purification and characterization
of the acylated intermediates.The α-phosphoryl group
was installed using a phosphitylation–oxidation
sequence.[28] Hydrogenolysis afforded the
anomeric lactol, which was exposed to dibenzyl N,N-diisopropylphosphoramidite in the presence of 1H-tetrazole.[29] The intermediate glycosyl
phosphite was oxidized in situ to yield a phosphotriester.
The benzyl protecting groups were removed by reductive hydrogenation
in the presence of an amine base to afford phosphomonoester 6 in good yield, with 9:1 α:β selectivity favoring
the desired anomer.A critical transformation was joining disaccharide 6 with lipid 7 to form the phosphonophosphate.
Activation
of the phosphoryl group of either coupling partner through formation
of the phosphoryl chloride or phosphoryl imidazolide could result
in self-coupling side products or product instability under the reaction
conditions. Ultimately, Moffatt–Khorana conditions[30] were effective. The electrophilic component,
C15 isoprenyl phosphonomorpholidate 7, was
prepared in four steps from (2Z,6Z)-farnesol (see Supporting Information). Disaccharide 6 and morpholidate 7 were
exposed to 1H-tetrazole, and the product was saponified
to afford phosphonophosphate 2. Though the yield was
modest, the transformation was highly reproducible. We exploited this
convergent synthetic route to produce acceptors to probe the structural
features required for enzymatic activity. Surrogate 8 bearing a C10 isoprenyl (neryl) lipid carrier as well
as surrogate 9 bearing only a monosaccharide were generated.
The stability of the allylic phosphonophosphate derivatives facilitated
their synthesis and subsequent analysis.The ability of the
acceptor surrogates to serve as substrates was
tested using purified GlfT1. Recombinant His6-tagged Mycobacterium smegmatis GlfT1 was produced in M.
smegmatis mc2155 and isolated by affinity chromatography.
Exposure of disaccharide 2 to GlfT1 in the presence of
donorsugar UDP-Galf[31] afforded oligosaccharide products (Figure 2), indicating that compound 2 is an effective substrate.
Mass spectrometry analysis indicated that the major product is extension
of the acceptor by +2 Galf units. NMR data for the
isolated product were consistent with those of a related tetrasaccharide[32] (see Supporting Information). A product extended by +3 Galf units is also observed.
GlfT1 consumes nearly all of the acceptor to produce these oligosaccharides.
Figure 2
Top: Representative
MALDI-TOF mass spectrum obtained from a reaction
mixture of compound 2, UDP-Galf, and
GlfT1. Masses corresponding to +2 and +3 Galf residues
were observed. Bottom: Corresponding +2 and +3 products from elongation
of acceptor 2. The linkage pattern shown is in agreement
with that of endogenous galactan (see ref (10)).
Top: Representative
MALDI-TOF mass spectrum obtained from a reaction
mixture of compound 2, UDP-Galf, and
GlfT1. Masses corresponding to +2 and +3 Galf residues
were observed. Bottom: Corresponding +2 and +3 products from elongation
of acceptor 2. The linkage pattern shown is in agreement
with that of endogenous galactan (see ref (10)).The +1 product was not observed. This result is consistent
with
processing of the natural substrate by microsomal preparations of
GlfT1.[17] These results indicate that the
phosphonophosphate acceptor emulates the natural substrate. The absence
of the +1 product is notable given that the polymerase GlfT2 can elongate
an acceptor with a single Galf residue.[16] We postulate that the ability of GlfT2 to generate
a polymer with faithfully alternating β-(1,5) and β-(1,6)
linkages arises from GlfT1-catalyzed formation of the +2 Galf disaccharide. In this way, GlfT1 sets the register for
polymerization by GlfT2.[13,33,34] The +2 disaccharide product may also lead to more efficient polymerization
by GlfT2. We previously showed that GlfT2 exhibits a kinetic lag phase
when polymerizing a lipid-linked Galf disaccharide.[13] The lag phase was abrogated with a substrate
bearing a Galf tetrasaccharide, as this oligosaccharide
presumably fills the monomer subsites during polymerization.[33] Thus, the tetrasaccharide product generated
by the action of GlfT1 should be processed rapidly by GlfT2.The identity of the lipid carrier can affect a substrate’s
ability to serve as a glycosyl acceptor. We therefore analyzed the
efficiency of elongation of substrates bearing different lipids by
quantifying the amount of UDP released upon GlfT1 addition. Specifically,
the assay employed couples UDP production to the luciferase/luciferin
reaction, wherein UDP production by GlfT1 is related linearly to increases
in luminescence (Figure 3, top).[35] As expected, no GlfT1 activity was observed
with monosaccharide 9, highlighting that GlfT1 requires
a substrate bearing the disaccharide l-Rha-α-(1,3)-d-GlcNAc (Figure 3, bottom). The difference
between C10-linked 8 and C15-linked 2 was pronounced. GlfT1 treatment produces almost 5 times
as much UDP in the presence of acceptor 2 than with 8. These data indicate that acceptor 2, with
its longer (2Z,6Z)-farnesyl lipid,
is a superior enzyme substrate. We used this assay to compare the
kinetics of elongation by GlfT1 and determined an apparent Km of 86 ± 25 μM for acceptor 2 and an apparent Vmax of 1.53
± 0.16 μM/min. We previously found that the lipid substituent
is important for the binding and processing of acceptors by GlfT2,[13] and our results suggest the lipid is also an
important component for GlfT1 acceptor substrates.
Figure 3
Top: Glycosyltransferase
activity promotes UDP release, which is
monitored using a luminescence assay. Bottom: Relative output of UDP-Galf turnover by GlfT1 with acceptors 2, 8, and 9.
Top: Glycosyltransferase
activity promotes UDP release, which is
monitored using a luminescence assay. Bottom: Relative output of UDP-Galf turnover by GlfT1 with acceptors 2, 8, and 9.The finding that phosphonophosphate analogues serve as effective
substrates reveals fundamental features of GlfT1. These acceptors,
the closest mimics of the natural substrate available, are processed
to lipid-linked oligosaccharides by GlfT1. These observations indicate
that the activity of GlfT1 outside of the endogenous mycobacterial
milieu is robust—it does not require the presence of membranes
or cell envelope components. Though similar GT-A domains and significant
amino acid sequence identity (24% by ClustalO alignment) suggest an
evolutionary link between GlfT1 and GlfT2, our data highlight their
distinct roles in galactan assembly. Specifically, GlfT1 does not
efficiently process O-alkyl disaccharides, but it does elongate lipid-linked
pyrophosphate or phosphonophosphate acceptors substituted with the
disaccharide l-Rha-α-(1,3)-d-GlcNAc by two
to three Galf residues. Unlike the polymerase GlfT2,
GlfT1 does not generate longer polymers and its substrate preference
appears to be more narrowly defined. Indeed, GlfT2 is a relatively
promiscuous carbohydrate polymerase that can act on varied truncated
lipid-linked acceptors.[16,36] The high specificity
of GlfT1 and its ability to append at least two Galf residues should yield substrates that can be rapidly polymerized
by GlfT2 to afford polysaccharides of defined sequence. These data
highlight the key role of GlfT1 in controlling galactan biosynthesis.Our studies of GlfT1 highlight the utility of the phosphonophosphate-containing
acceptor substrates. The substitution of a phosphonophosphate for
a pyrophosphate can facilitate the synthesis of complex glycosyltransferase
acceptors. Glycosyltransferases in prokaryotes, eukaryotes, and archaea
that act on pyrophosphate-linked acceptors are ubiquitous, including
enzymes that mediate peptidoglycan assembly[6,37] and
that generate O-[38,39] and N-linked[5] glycans. We anticipate that the approach described herein
will facilitate characterization of glycosyltransferase activity of
the large family of enzymes that act on pyrophosphate-containing acceptors.
Authors: Amirreza Faridmoayer; Messele A Fentabil; Dominic C Mills; John S Klassen; Mario F Feldman Journal: J Bacteriol Date: 2007-09-21 Impact factor: 3.490
Authors: Mark M Chen; Eranthie Weerapana; Ewa Ciepichal; Jacek Stupak; Christopher W Reid; Ewa Swiezewska; Barbara Imperiali Journal: Biochemistry Date: 2007-11-23 Impact factor: 3.162
Authors: Phillip J Calabretta; Heather L Hodges; Matthew B Kraft; Victoria M Marando; Laura L Kiessling Journal: J Am Chem Soc Date: 2019-06-04 Impact factor: 15.419
Authors: Charlotte Olagnon; Julia Monjaras Feria; Clemens Grünwald-Gruber; Markus Blaukopf; Miguel A Valvano; Paul Kosma Journal: Chembiochem Date: 2019-10-22 Impact factor: 3.164
Authors: Shiva Kumar Angala; Maju Joe; Michael R McNeil; Avraham Liav; Todd L Lowary; Mary Jackson Journal: ACS Chem Biol Date: 2020-12-31 Impact factor: 5.100